|
US9266891B2
(en)
|
2012-11-16 |
2016-02-23 |
Boehringer Ingelheim International Gmbh |
Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
|
|
US9073878B2
(en)
|
2012-11-21 |
2015-07-07 |
Zenith Epigenetics Corp. |
Cyclic amines as bromodomain inhibitors
|
|
US9765039B2
(en)
|
2012-11-21 |
2017-09-19 |
Zenith Epigenetics Ltd. |
Biaryl derivatives as bromodomain inhibitors
|
|
JP2016507496A
(ja)
|
2012-12-21 |
2016-03-10 |
ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． |
ブロモドメイン阻害剤としての新規複素環式化合物
|
|
ES2755827T3
(es)
|
2013-03-15 |
2020-04-23 |
Incyte Holdings Corp |
Heterciclos tricíclicos como inhibidores de proteína BET
|
|
HK1217484A1
(zh)
|
2013-04-26 |
2017-01-13 |
百济神州有限公司 |
取代的5-(3，5-二甲基异恶唑-4-基)二氢吲哚-2-酮类衍生物
|
|
EP3010917B1
(en)
|
2013-06-21 |
2018-01-31 |
Zenith Epigenetics Ltd. |
Novel substituted bicyclic compounds as bromodomain inhibitors
|
|
NZ754629A
(en)
|
2013-06-21 |
2021-07-30 |
Zenith Epigenetics Ltd |
Novel bicyclic bromodomain inhibitors
|
|
US9290514B2
(en)
|
2013-07-08 |
2016-03-22 |
Incyte Holdings Corporation |
Tricyclic heterocycles as BET protein inhibitors
|
|
CN105593224B
(zh)
|
2013-07-31 |
2021-05-25 |
恒元生物医药科技(苏州)有限公司 |
作为溴结构域抑制剂的新型喹唑啉酮类化合物
|
|
WO2015081203A1
(en)
|
2013-11-26 |
2015-06-04 |
Incyte Corporation |
Bicyclic heterocycles as bet protein inhibitors
|
|
WO2015081189A1
(en)
|
2013-11-26 |
2015-06-04 |
Incyte Corporation |
Bicyclic heterocycles as bet protein inhibitors
|
|
US9309246B2
(en)
|
2013-12-19 |
2016-04-12 |
Incyte Corporation |
Tricyclic heterocycles as BET protein inhibitors
|
|
RS64231B1
(sr)
|
2014-04-23 |
2023-06-30 |
Incyte Holdings Corp |
1h-pirolo[2,3-c]piridin-7(6h)-on i pirazolo[3,4-c]piridin-7(6h)-on kao inhibitori bet proteina
|
|
US9902702B2
(en)
*
|
2014-07-15 |
2018-02-27 |
Bristol-Myers Squibb Company |
Spirocycloheptanes as inhibitors of rock
|
|
JP6599979B2
(ja)
|
2014-09-15 |
2019-10-30 |
インサイト・コーポレイション |
Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
|
|
JP6788584B2
(ja)
|
2014-10-31 |
2020-11-25 |
マサチューセッツ インスティテュート オブ テクノロジー |
Ｃｒｉｓｐｒについての超並列コンビナトリアル遺伝学
|
|
WO2016087942A1
(en)
*
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Corp. |
Substituted pyridines as bromodomain inhibitors
|
|
US10710992B2
(en)
|
2014-12-01 |
2020-07-14 |
Zenith Epigenetics Ltd. |
Substituted pyridinones as bromodomain inhibitors
|
|
HK1245248B
(en)
|
2014-12-11 |
2020-05-15 |
恒翼生物医药(上海)股份有限公司 |
Substituted heterocycles as bromodomain inhibitors
|
|
CN107406438B
(zh)
|
2014-12-17 |
2021-05-14 |
恒翼生物医药科技(上海)有限公司 |
溴结构域的抑制剂
|
|
EP3310772A1
(en)
*
|
2015-06-16 |
2018-04-25 |
Orion Corporation |
Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
|
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
|
TW201722966A
(zh)
|
2015-10-29 |
2017-07-01 |
英塞特公司 |
Bet蛋白質抑制劑之非晶固體形式
|
|
PE20190623A1
(es)
|
2016-06-20 |
2019-04-26 |
Incyte Corp |
Formas solidas cristalinas de un inhibidor de bet
|
|
WO2018109271A1
(en)
*
|
2016-12-13 |
2018-06-21 |
Orion Corporation |
New bromodomain inhibitors
|
|
CN107739370B
(zh)
*
|
2017-10-26 |
2021-03-30 |
中国药科大学 |
吡咯酮类brd4蛋白抑制剂的制备方法以及用途
|
|
CN109928979B
(zh)
*
|
2017-12-15 |
2021-08-06 |
四川科伦博泰生物医药股份有限公司 |
吲哚酮类衍生物及其制备方法和用途
|
|
CN108383771A
(zh)
*
|
2018-01-08 |
2018-08-10 |
华东师范大学 |
手性3,3-二取代异吲哚啉-1-酮衍生物及其合成方法和应用
|
|
WO2020046813A1
(en)
*
|
2018-08-27 |
2020-03-05 |
Arcus Biosciences, Inc. |
Cd73 inhibitors
|
|
US11396502B2
(en)
|
2018-11-13 |
2022-07-26 |
Incyte Corporation |
Substituted heterocyclic derivatives as PI3K inhibitors
|
|
US11078204B2
(en)
|
2018-11-13 |
2021-08-03 |
Incyte Corporation |
Heterocyclic derivatives as PI3K inhibitors
|
|
US11161838B2
(en)
|
2018-11-13 |
2021-11-02 |
Incyte Corporation |
Heterocyclic derivatives as PI3K inhibitors
|
|
WO2020210366A1
(en)
|
2019-04-09 |
2020-10-15 |
Plexxikon Inc. |
Condensed azines for ep300 or cbp modulation and indications therefor
|
|
CN120623106A
(zh)
|
2019-09-30 |
2025-09-12 |
协和麒麟株式会社 |
Bet降解剂
|
|
WO2021175432A1
(en)
|
2020-03-04 |
2021-09-10 |
Boehringer Ingelheim International Gmbh |
Method for administration of an anti cancer agent
|
|
EP3912625A1
(en)
|
2020-05-20 |
2021-11-24 |
Kaerus Bioscience Limited |
Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
WO2024049929A2
(en)
*
|
2022-08-30 |
2024-03-07 |
Pannex Therapeutics Inc. |
Pannexin-1 modulators and methods of treating disorders in which pannexin-1 is implicated
|